Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level

European Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2011, Pages 129-134

  Kim, Kyoung Ah ^a   Joo, Hyun Jin ^a   Park, Ji Young ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

A771726; ABCG2; BCRP; Leflunomide; Uric acid

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; LEFLUNOMIDE; TERIFLUNOMIDE; URIC ACID;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME ANALYSIS; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MUTATIONAL ANALYSIS; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANILINE COMPOUNDS; ATP-BINDING CASSETTE TRANSPORTERS; GENOTYPE; HUMANS; HYDROXYBUTYRATES; ISOXAZOLES; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODRUGS; PROTEIN TRANSPORT; URIC ACID;

EID: 79151472175     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0916-0     Document Type: Article

References (38)

1. T Litman TE Druley WD Stein SE Bates 2001 From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell Mol Life Sci 58 931 959 1:CAS:528:DC%2BD3MXlvFSms74%3D 10.1007/PL00000912 11497241
2. JW Jonker JW Smit RF Brinkhuis M Maliepaard JH Beijnen JH Schellens, et al. 2000 Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan J Natl Cancer Inst 92 1651 1656 1:CAS:528:DC%2BD3cXnvV2mtbw%3D 10.1093/jnci/92.20.1651 11036110
3. RW Robey WY Medina-Perez K Nishiyama T Lahusen K Miyake T Litman, et al. 2001 Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells Clin Cancer Res 7 145 152 1:CAS:528:DC%2BD3MXht1Whtrg%3D 11205902
4. CP Zamber JK Lamba K Yasuda J Farnum K Thummel JD Schuetz, et al. 2003 Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine Pharmacogenetics 13 19 28 1:CAS:528:DC%2BD3sXlsFGrug%3D%3D 10.1097/00008571-200301000-00004 12544509
5. Y Imai M Nakane K Kage S Tsukahara E Ishikawa T Tsuruo, et al. 2002 C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance Mol Cancer Ther 1 611 616 1:CAS:528:DC%2BD38XlsFSlsr4%3D 12479221
6. C Kondo H Suzuki M Itoda S Ozawa J Sawada D Kobayashi, et al. 2004 Functional analysis of SNPs variants of BCRP/ABCG2 Pharm Res 21 1895 1903 1:CAS:528:DC%2BD2cXos1Wqtrk%3D 10.1023/B:PHAM.0000045245.21637.d4 15553238
7. FA de Jong S Marsh RH Mathijssen C King J Verweij A Sparreboom, et al. 2004 ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition Clin Cancer Res 10 5889 5894 10.1158/1078-0432.CCR-04-0144 15355921
8. P Breedveld N Zelcer D Pluim O Sonmezer MM Tibben JH Beijnen, et al. 2004 Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions Cancer Res 64 5804 5811 1:CAS:528:DC%2BD2cXmslaksrY%3D 10.1158/0008-5472.CAN-03-4062 15313923
9. G Cusatis V Gregorc J Li A Spreafico RG Ingersoll J Verweij, et al. 2006 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib J Natl Cancer Inst 98 1739 1742 1:CAS:528:DC%2BD28XhtlCru7nF 10.1093/jnci/djj469 17148776
10. A Sparreboom WJ Loos H Burger TM Sissung J Verweij WD Figg, et al. 2005 Effect of ABCG2 genotype on the oral bioavailability of topotecan Cancer Biol Ther 4 650 658 1:CAS:528:DC%2BD28Xjt1Krt7o%3D 15908806
11. A Dehghan A Kottgen Q Yang SJ Hwang WL Kao F Rivadeneira, et al. 2008 Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study Lancet 372 1953 1961 1:CAS:528: DC%2BD1cXhsVKlsLrF 10.1016/S0140-6736(08)61343-4 18834626
12. M Kolz T Johnson S Sanna A Teumer V Vitart M Perola, et al. 2009 Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations PLoS Genet 5 e1000504 10.1371/journal.pgen.1000504 19503597
13. MM Goldenberg 1999 Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis Clin Ther 21 1837 1852 1:CAS:528: DC%2BD3cXivFGitQ%3D%3D 10.1016/S0149-2918(00)86732-6 10890256 discussion 1821
14. VP Kale LS Bichile 2004 Leflunomide: a novel disease modifying anti-rheumatic drug J Postgrad Med 50 154 157 15235221
15. E Kis T Nagy M Jani E Molnar J Janossy O Ujhellyi, et al. 2009 Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance Ann Rheum Dis 68 1201 1207 1:CAS:528: DC%2BD1MXovVCms78%3D 10.1136/ard.2007.086264 18397960
16. J Li HW Yao Y Jin YF Zhang CY Li YH Li, et al. 2002 Pharmacokinetics of leflunomide in Chinese healthy volunteers Acta Pharmacol Sin 23 551 555 1:CAS:528:DC%2BD38XksVGrs7k%3D 12060531
17. JY Park KA Kim YH Lee SW Park GH Lee JH Ryu 2010 Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: a single dose, randomized, open-label, two-way crossover study Int J Clin Pharmacol Ther 48 291 295 1:CAS:528:DC%2BC3cXntValu7k%3D 20353751
18. KA Kim PW Park SJ Hong JY Park 2008 The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 236 242 1:CAS:528: DC%2BD1cXptlyktLc%3D 10.1038/clpt.2008.20 18323861
19. Park JY, Kim KA, Joo HJ (2009) Multiplex pyrosequencing analysis of the most common ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population. J Clin Pharm Ther (Submitted)
20. ML Herrmann R Schleyerbach BJ Kirschbaum 2000 Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases Immunopharmacology 47 273 289 1:CAS:528:DC%2BD3cXktlKktL0%3D 10.1016/S0162-3109(00)00191-0 10878294
21. HT Silva Junior RE Morris 1997 Leflunomide and malononitrilamides Am J Med Sci 313 289 301 1:STN:280:DyaK2s3ptVersA%3D%3D 10.1097/00000441-199705000- 00008 9145039
22. DR James CP Price 1984 Problems associated with the measurement of uric acid using two enzyme-mediated reaction systems Ann Clin Biochem 21 Pt 5 405 410 1:CAS:528:DyaL2cXlvVOiurw%3D 6508211
23. B Rozman 2002 Clinical pharmacokinetics of leflunomide Clin Pharmacokinet 41 421 430 1:CAS:528:DC%2BD38XlvFKmtbc%3D 10.2165/00003088-200241060-00003 12074690
24. AS Kalgutkar HT Nguyen AD Vaz A Doan DK Dalvie DG McLeod, et al. 2003 In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes Drug Metab Dispos 31 1240 1250 1:CAS:528:DC%2BD3sXnslKitro%3D 10.1124/dmd.31.10.1240 12975333
25. V Chan BG Charles SE Tett 2005 Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis Br J Clin Pharmacol 60 257 264 1:CAS:528:DC%2BD2MXhtFSnsr%2FJ 10.1111/j.1365-2125. 2005.02415.x 16120064
26. Y Honjo CA Hrycyna QW Yan WY Medina-Perez RW Robey A van de Laar, et al. 2001 Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells Cancer Res 61 6635 6639 1:CAS:528: DC%2BD3MXntFaisr0%3D 11559526
27. H Mitomo R Kato A Ito S Kasamatsu Y Ikegami I Kii, et al. 2003 A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport Biochem J 373 767 774 1:CAS:528:DC%2BD3sXlslOhurk%3D 10.1042/BJ20030150 12741957
28. SS Lee HE Jeong JM Yi HJ Jung JE Jang EY Kim, et al. 2007 Identification and functional assessment of BCRP polymorphisms in a Korean population Drug Metab Dispos 35 623 632 1:CAS:528:DC%2BD2sXktVOntLs%3D 10.1124/dmd.106.012302 17237154
29. A Sparreboom H Gelderblom S Marsh R Ahluwalia R Obach P Principe, et al. 2004 Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype Clin Pharmacol Ther 76 38 44 1:CAS:528:DC%2BD2cXlsVaqtrs%3D 10.1016/j.clpt.2004.03. 003 15229462
30. Y Yamasaki I Ieiri H Kusuhara T Sasaki M Kimura H Tabuchi, et al. 2008 Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans Clin Pharmacol Ther 84 95 103 1:CAS:528:DC%2BD1cXnt1KqsLw%3D 10.1038/sj.clpt.6100459 18167504
31. S Mizuarai N Aozasa H Kotani 2004 Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 Int J Cancer 109 238 246 1:CAS:528:DC%2BD2cXhvVCksrs%3D 10.1002/ijc.11669 14750175
32. A Tamura Y Onishi R An S Koshiba K Wakabayashi K Hoshijima, et al. 2007 In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs Drug Metab Pharmacokinet 22 428 440 1:CAS:528:DC%2BD1cXit1ygt74%3D 10.2133/dmpk.22.428 18159130
33. OM Woodward A Kottgen J Coresh E Boerwinkle WB Guggino M Kottgen 2009 Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout Proc Natl Acad Sci USA 106 10338 10342 1:CAS:528:DC%2BD1MXot1Gitbk%3D 10.1073/pnas.0901249106 19506252
34. Kunkel G, Cannon GW (2006) Leflunomide in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2
35. GW Cannon WL Holden J Juhaeri W Dai L Scarazzini P Stang 2004 Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD J Rheumatol 31 1906 1911 1:CAS:528:DC%2BD2cXps1agtrY%3D 15468352
36. G Merino AE van Herwaarden E Wagenaar JW Jonker AH Schinkel 2005 Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver Mol Pharmacol 67 1765 1771 1:CAS:528:DC%2BD2MXktFegtLk%3D 10.1124/mol.105.011080 15722455
37. P Bohanec Grabar B Rozman M Tomsic D Suput D Logar V Dolzan 2008 Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients Eur J Clin Pharmacol 64 871 876 1:CAS:528:DC%2BD1cXhtVKju7bO 10.1007/s00228-008-0498-2 18496682
38. P Bohanec Grabar I Grabnar B Rozman D Logar M Tomsic D Suput, et al. 2009 Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis Drug Metab Dispos 37 2061 2068 10.1124/dmd.109.027482 19581389